Lipovax-Fg115 is an adjuvanted delivery vehicle for recombinant antigens.
The platform exploits the commonly used his-tag to attach multiple copies of one or more type of antigens to the surface Lipovax-Fg115 particles.
Our proprietary Fg115 molecules are also attached to the liposomes to stimulate the TLR5 receptor. The platform improves vaccine internalisation by dendritic cells and results in increased cross presentation. In vivo this translates in increased T cell and antibody and responses.